Hence, in this study, we explored the association between the mutated IL-1 signaling status and the prognosis of COAD patients receiving ICIs and sought to illustrate the potential mechanism between the mutated IL-1 signaling status and the prognosis of patients treated with immunotherapy from the perspective of the immune microenvironment. The gene discussed is IL1B; the disease is colon adenocarcinoma.